Clients in the media Clients IN the MEDIA

Ensuring your story is visible.

Acepodia: linking antitumor antibodies to immune cells

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy, led JW Therapeutics to partner with the company for commercialization of its lead program Tuesday.

Antibacterial activity against MRSA

Recce Pharmaceuticals Ltd., which is developing a new class of broad-spectrum synthetic antibiotics, announced positive data showing significant in-vivo antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) in rats with topical burns treated with its lead compound RECCE 327.

CalciMedica’s Auxora Shows Promise As COVID-19 Treatment, Patients Recovered Twice As Fast

Biotech firm CalciMedica announced Thursday its anti-inflammatory drug Auxora is showing promise in treating COVID-19 when combined with standard care, reducing ventilator use by half and speeding recovery.

Developing Synthetic Antibiotics Against Drug-Resistant Pathogens

Technology Networks spoke with James Graham, Executive Director at Recce Pharmaceuticals, to learn more about how synthetic antibiotics differ from those derived from natural sources. He also discusses how the company has developed a novel class of synthetic antibiotics and elaborates on their mechanism of action.

AACR: FUSION PROTEIN SO-C101 WITH PEMBRO IN ADULT PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS

Sotio is developing an IL-15 superagonist, SO-C101, as a potent immunotherapy for patients with cancer. This study examined SO-C101 in multiple tumor mouse models alone and in combination with PD-1 inhibition. 

San Diego biotech’s drug shows early promise in treating COVID-19 pneumonia

CalciMedica’s preliminary results will be put to the test in a larger clinical trial. San Diego biotech CalciMedica announced Thursday that an experimental drug it is testing to help COVID-19 patients stay off ventilators and recover sooner shows early signs of achieving both goals.

Targeting Diseases of Aging at a Cellular Level

To see the affects of aging all you have to do is look in a mirror and watch the changes over time. Fountain Therapeutics is training its artificial intelligence platform to look at individual cells to detect changes that occur as cells get older and discover therapeutics that target underlying mechanisms of aging. The company believes this will provide new ways to target therapies to treat a range of diseases associated with aging. We spoke to John Dimos, CEO of Fountain, about the company’s AI platform, it’s approach to understanding aging at a cellular level, and how it provides new ways of discovering and developing therapeutics for diseases of aging

Boasting antibody-cell conjugation, Acepodia licenses out two cell therapies to JW Therapeutics

Taiwan biotech Acepodia Inc., of Burlingame, Calif., and Taipei, has licensed out two of its cell therapy candidates, ACE-1702 and ACE-1655, to Chinese CAR T therapy developer JW Therapeutics (Shanghai) Co. Ltd. to develop and commercialize them in China, Hong Kong and Macau. Acepodia will receive up-front and milestone payments from JW Therapeutics, plus royalties on sales.